Australia's drug regulatory agency, Therapeutic Products Administration, announced that it recognizes BBIBP-CorV COVID-19 vaccines developed by Sinopharm of China and Covaxin vaccines produced by India's Bharat Biotech company.
The Therapeutic Goods Administration (TGA), Australia's drug regulatory agency, announced that passengers who have BBIBP-CorV and Covaxin vaccines, which are not yet in use in Australia but are widely applied in many countries, will be accepted as fully vaccinated when they enter the country with the opening of the Australian borders.
Explaining that the vaccines in question provide protection against the virus and that they have obtained additional information showing that a potential inbound passenger reduces the possibility of transmitting the infection to others or getting sick due to Kovid-19 while in Australia, TGA stated that they decided to recognize the vaccines, taking into account the information given by the World Health Organization. .
In Australia, where vaccines developed by AstraZeneca, Pfizer-BioNTech and Moderna are implemented, 16 percent of the population over the age of 77,5 who are eligible for the vaccine has a double dose vaccine, while the rate of those who have a single dose has reached 88,3 percent.
Source: China International Radio